Efficacy looks better with daraxonrasib plus chemo versus monotherapy, but toxicity looms.

So far the data, with a Car-T Legend licensed to Novartis, lag antibody approaches.

But first it will need to identify the optimal dose in first-line small-cell lung cancer.

Pivotal data set the stage for slightly delayed US accelerated approval filing.

Inlexzo gets the nod in BCG-unresponsive non-muscle invasive bladder cancer, but the group has bigger plans.

Global data are in the same ballpark as Chinese results presented earlier this year.